文献速递消化道肿瘤与早癌消化内镜

多靶点粪便DNA筛查在临床实践中对结直肠肿瘤具有高阳性预测值且不受既往结肠镜检查影响

Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该研究在39个月内纳入16469例完成多靶点粪便DNA(MT-sDNA)检测的患者,其中2326例(14.1%)检测阳性。排除结直肠癌高风险患者后,1801例中1558例(87%)接受了诊断性结肠镜检查,任何结直肠肿瘤的阳性预测值(PPV)为67%,且无论既往是否接受过结肠镜检查,PPV均保持高位。

要点

  • MT-sDNA检测阳性后,诊断性结肠镜对任何结直肠肿瘤的PPV为67%。
  • 无既往结肠镜者肿瘤检出率73%,有既往结肠镜者仍达63%(P<0.0001)。
  • 大多数(79%)阳性患者为右侧结直肠肿瘤。

核心结论

  • MT-sDNA对任何结直肠肿瘤具有高阳性预测值,且不受既往结肠镜检查暴露影响。
  • MT-sDNA阳性患者中大多数为右侧结直肠肿瘤,可能优于其他现有筛查方式。

研究设计与样本

  • 回顾性研究,连续纳入39个月内完成MT-sDNA检测的患者,并复习阳性者诊断性结肠镜记录。
  • 16469例完成检测,2326例(14.1%)阳性;排除高风险后1801例,其中1558例(87%)接受结肠镜。

主要发现

  • 1558例中1046例发现任何结直肠肿瘤,PPV=67%。
  • 无既往结肠镜者肿瘤检出率73%,有既往结肠镜者63%(P<0.0001)。
  • 79%的患者为右侧结直肠肿瘤。

关键数值与推荐

  • MT-sDNA检测阳性率14.1%(2326/16469)。
  • 诊断性结肠镜依从率87%(1558/1801)。
  • 任何结直肠肿瘤PPV=67%(1046/1558)。

临床怎么用

  • MT-sDNA阳性后应积极转诊诊断性结肠镜,无论患者既往是否接受过结肠镜。
  • 解读阳性结果时需注意右侧结直肠肿瘤占多数。

局限性

  • 回顾性设计,仅纳入完成MT-sDNA检测并阳性后接受结肠镜的患者。
  • 排除结直肠癌高风险患者,结果可能不适用于该人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Multitarget stool DNA (MT-sDNA) testing has grown as a noninvasive screening modality for colorectal cancer (CRC), but real-world clinical data are limited in the post-FDA approval setting. The effect of previous colonoscopy on MT-sDNA performance is not known. We aimed to evaluate findings of colorectal neoplasia (CRN) at diagnostic colonoscopy in patients with positive MT-sDNA testing, stratified by patient exposure to previous colonoscopy. METHODS: We identified consecutive patients completing MT-sDNA testing over a 39-month period and reviewed the records of those with positive tests for neoplastic findings at diagnostic colonoscopy. MT-sDNA test positivity rate, adherence to diagnostic colonoscopy, and the positive predictive value (PPV) of MT-sDNA for any CRN and neoplastic subtypes were calculated. RESULTS: Of 16,469 MT-sDNA tests completed, testing returned positive in 2,326 (14.1%) patients. After exclusion of patients at increased risk for CRC, 1,801 patients remained, 1,558 (87%) of whom underwent diagnostic colonoscopy; 918 of 1,558 (59%) of these patients had undergone previous colonoscopy, whereas 640 (41%) had not. Any CRN was found in 1,046 of 1,558 patients (PPV = 67%). More neoplastic lesions were found in patients without previous colonoscopy (73%); however, the rates remained high among those who had undergone previous colonoscopy (63%, P < 0.0001). The large majority (79%) of patients had right-sided neoplasia. DISCUSSION: MT-sDNA has a high PPV for any CRN regardless of exposure to previous colonoscopy. Right-sided CRN was found at colonoscopy in most patients with positive MT-sDNA testing, representing a potential advantage over other currently available screening modalities for CRC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Eckmann JD, Ebner DW, Bering J, et al. Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy. Am J Gastroenterol. 2020. PMID: 32068535. doi:10.14309/ajg.0000000000000546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。